SAN DIEGO, CA, Mar. 17, 2025 /Circular Genomics Communications/ —Circular Genomics, a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, today announced it is moving the company’s headquarters to Lilly Gateway Labs in San Diego, California, which is operated in partnership with Alexandria Real Estate Equities, Inc., to advance the development of Alzheimer’s disease (AD) biomarkers aimed at improving the identification and monitoring of the disease and its risk of progression. Circular Genomics was selected to join the community at Gateway Labs, a best-in-class innovation hub that connects pioneering biotechs to Eli Lilly and Company’s expertise, based on its cutting-edge circRNA platform technologies and promising diagnostic programs for neurological disorders.

“Joining Lilly Gateway Labs is a pivotal step for Circular Genomics,” said Paul Sargeant, PhD, Chief Executive Officer of Circular Genomics. “We believe that tapping into Lilly’s powerful neuroscience expertise, coupled with the operational support, resources, and scientific engagement available through Gateway Labs, will significantly advance the development of groundbreaking diagnostic and prognostic blood tests for Alzheimer’s disease.”

Read the full article on circulargenomics.com